NewGenIvf Group Limited (NIVFW) Stock Analysis

Company Overview

NewGenIvf Group Limited operates as an investment holding company focused on providing assisted reproductive services to couples and individuals seeking fertility treatments across Thailand, Cambodia, Hong Kong, and Kyrgyzstan. The organization delivers a comprehensive range of fertility treatment solutions, including in vitro fertilization, catering to specific regional medical markets. The company employs a workforce of 76 individuals to support its operational and service delivery functions within its international footprint. As an investment holding entity, the company's scale is characterized by a market cap that is not publicly disclosed, with reported annual revenue reaching $4.58 million and a relatively small employee base, indicating a niche operational structure rather than a mass-market commercial scale.

Financial Health

The company reports trailing twelve-month revenue of $4.58 million alongside a net income of $17.44 million, while reporting an EBITDA of -$6,801,572. The substantial gap between positive net income and negative EBITDA reveals a cost structure where significant non-cash expenses or accounting adjustments are driving the bottom line higher than the operating cash earnings typically associated with revenue generation. Free cash flow stands at -$8,526,913, indicating that current operations are consuming cash reserves rather than generating liquidity, which limits the company's financial flexibility for immediate capital expenditures or debt servicing without external financing. Profit margins are exceptionally high at 381.2%, while gross margins sit at 21.2% and operating margins are deeply negative at -195.9%, suggesting a complex accounting environment where revenue recognition differs significantly from operational profitability metrics. The balance sheet holds $3.15 million in cash against $5.50 million in debt, resulting in a debt-to-equity ratio of 19.15, which indicates a highly leveraged position where liabilities exceed equity significantly. Current liquidity is supported by a current ratio of 3.43, suggesting the company possesses sufficient current assets to cover short-term obligations more than three times over. Return on equity is reported at 160.5% while return on assets is -23.1%, revealing a scenario where equity is being amplified by financial leverage despite the underlying assets generating negative returns on an asset basis.

Valuation Assessment

Trailing P/E and forward P/E ratios are not available for NewGenIvf Group Limited, which prevents a standard earnings-based valuation comparison and implies that earnings trajectory expectations are either undefined or not reflected in traditional multiples. The price-to-book ratio is listed as 0.00, indicating that the market valuation of the company's stock does not exceed the book value of its shareholders' equity, or that the book value is not a meaningful metric for valuation in this specific context. Price-to-sales and EV/EBITDA multiples are also not available, meaning alternative valuation metrics that rely on sales volume or enterprise value relative to earnings cannot be calculated for this entity at this time. The stock trades with a 52-week high of $0.02 and a 52-week low of $0.01, and without a specific current price provided in the data, the exact percentage distance from the high cannot be calculated, but the range demonstrates a narrow trading band typical of low-priced securities. The beta value is 0.00, which implies that the stock price exhibits no volatility relative to the broader market, suggesting the asset moves independently of general market indices or possesses negligible price sensitivity to market fluctuations.

Growth & Income

Revenue growth year-over-year is reported at -12.9%, while earnings growth is not available, indicating that the company is currently contracting in terms of top-line sales generation. The absence of earnings growth data combined with negative revenue growth suggests that the company is not expanding its market share or increasing sales volume during this reporting period. As a non-dividend payer with no dividend yield or payout ratio available, the company reinvests all available earnings, if any, or capital back into its business operations rather than distributing income to shareholders. The overall growth and income profile is characterized by revenue contraction and a lack of dividend distribution, positioning the company as a pure play on future operational turnaround or market expansion potential rather than a current income generator.